8-K: STRATA Skin Sciences Announces Expansion of CPT Codes, Broadening Access to Excimer Laser Treatments

STRATA Skin Sciences announces the American Medical Association (AMA) has expanded reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions.

Summary

• STRATA Skin Sciences announced that the American Medical Association (AMA) has revised CPT codes 96920-96922 to expand reimbursement eligibility for excimer laser treatments.
• The expanded eligibility includes multiple inflammatory and auto-immune skin conditions beyond the original psoriasis indication.
• This change reflects over 20 years of clinical evidence and real-world use of STRATA's XTRAC Excimer Lasers.
• The updated CPT descriptor aligns the codes with current FDA clearances and commercial payer coverage guidelines.
• The changes are anticipated to reduce systemic denials and the need for prior authorizations.
• The revised language now explicitly includes the treatment of inflammatory and autoimmune skin conditions, enabling coverage for conditions such as vitiligo, atopic dermatitis, mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-cell lymphoma (CTCL).
• The company expects this change to expand direct and clear reimbursement paths and domestic market access from roughly 10 million psoriasis patients to over 30 million potential patients.
• Non-psoriasis indications already account for approximately 30% of excimer laser treatment volume, and the updated CPT codes remove key reimbursement barriers.
• STRATA anticipates this change will drive broader adoption of the XTRAC platform beyond the existing 1,400 clinics and 4,000 medical providers using it domestically, expand addressable procedure volume, and support accelerated revenue growth under its recurring-use business model.
• STRATA has approximately 850 recurring revenue devices owned in the United States.

Sentiment

Score: 9

Explanation: The announcement is highly positive due to the expanded CPT codes, which are expected to drive significant commercial growth and broader adoption of STRATA's XTRAC platform. The management's comments and the involvement of key opinion leaders further contribute to the positive sentiment.

Positives

• Expanded CPT codes will broaden access to STRATA's XTRAC excimer laser treatments for patients with inflammatory and auto-immune skin conditions.
• The updated codes are expected to reduce systemic denials and the need for prior authorizations.
• STRATA anticipates significant commercial growth and broader adoption of the XTRAC platform.
• The company expects to expand market access from 10 million psoriasis patients to over 30 million potential patients.
• The change validates the broader clinical utility of the XTRAC excimer laser.

Risks

• The company's ability to achieve the anticipated commercial growth depends on various factors, including market conditions, regulatory changes, and competition.
• The forward-looking statements are subject to significant uncertainties and changes in circumstances, as detailed in the company's SEC reports.

Future Outlook

STRATA expects the expanded CPT code coverage to generate significant commercial growth, drive broader adoption of the XTRAC platform, expand addressable procedure volume, and support accelerated revenue growth under its recurring-use business model.

Management Comments

• Dr. Dolev Rafaeli, STRATA CEO, stated that this CPT update validates volumes of data demonstrating the utility of excimer laser beyond psoriasis and supports the company's mission to expand access to safe, effective, non-drug dermatologic solutions.
• Dr. Mark Lebwohl noted that the CPT code update strongly validates 308nm excimer laser's broader clinical value and represents a vital step toward expanding patient access.
• Dr. Grimes added that this update is a major victory for the vitiligo community and will allow more patients to benefit safely, affordably, and equitably.
• Dr. Richard emphasized that this update safeguards the access to excimer laser treatments.

Industry Context

This announcement reflects a broader trend in the medical technology industry towards expanding access to innovative treatments through favorable reimbursement policies. The expansion of CPT codes for excimer laser treatments positions STRATA Skin Sciences to capitalize on the growing demand for non-drug dermatologic solutions.

Comparison to Industry Standards

• The expansion of CPT codes for excimer laser treatments aligns with industry efforts to improve patient access to advanced therapies.
• Companies like PhotoMedex (now part of Valeant Pharmaceuticals) have also focused on light-based therapies for dermatological conditions.
• The 30% of excimer laser procedures treating non-psoriasis conditions based on 2023 Medicare data indicates a significant existing demand for these treatments beyond the initial psoriasis indication.
• The potential expansion to 30 million patients positions STRATA to compete with other companies offering treatments for vitiligo, atopic dermatitis, and other inflammatory skin conditions.

Stakeholder Impact

• Shareholders: Positive impact due to anticipated commercial growth and increased revenue.
• Patients: Improved access to excimer laser treatments for various skin conditions.
• Medical Providers: Broader adoption of the XTRAC platform and increased reimbursement opportunities.
• Payers/Insurers: Potential for cost-effective treatment options compared to drugs.

Key Dates

Keywords

STRATA Skin Sciences, XTRAC Excimer Laser, CPT Codes, Reimbursement, Dermatology, Vitiligo, Psoriasis, Atopic Dermatitis, Inflammatory Skin Diseases, Auto-Immune Skin Diseases